Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety,
tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo
in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease
(PD). NLX-112 will be up-titrated to either 2 mg/day or to the highest well-tolerated dose
less than 2 mg/day over 4 weeks, maintained at the well-tolerated dose for an additional 2
weeks, and then down-titrated over 2 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Neurolixis SAS
Collaborators:
CTC Clinical Trial Consultants AB Michael J. Fox Foundation for Parkinson's Research Parkinson´s UK